{"id":"W4399667123","doi":"10.1200/jco.2024.42.16_suppl.3104","title":"Binimetinib and encorafenib for the treatment of advanced solid tumors with non-V600E BRAF mutations (mts): Final results of the investigator-initiated phase II BEAVER trial.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Melanoma and MAPK Pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":7,"is_retracted":false,"has_abstract":true,"ca_institutions":"Ontario Institute for Cancer Research; Princess Margaret Cancer Centre; University of Toronto; University Health Network; McGill University; Jewish General Hospital","funders":"Jewish General Hospital; Pfizer; Conquer Cancer Foundation","keywords":"Medicine; Internal medicine; Oncology; Mutation; Clinical trial; Solid tumor; Cancer research; Cancer; Genetics; Gene","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001274647,0.0007057882,0.0008365745,0.0002797225,0.0002146093,0.000901211,0.0003941166,0.0006736593,0.004167152],"category_scores_gemma":[0.0008814957,0.0002490701,0.0006769829,0.0002894281,0.0003320081,0.0007311463,0.0003656723,0.0016902,0.0005736666],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005768646,"about_ca_system_score_gemma":0.000850795,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007849457,"about_ca_topic_score_gemma":0.003701989,"domain_scores_codex":[0.9997019,0.0001321783,0.00001418898,0.00003960968,0.00004515201,0.00006688759],"domain_scores_gemma":[0.9996938,0.00005408296,0.00007166598,0.00001869503,0.0000243268,0.0001375181],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.7203777,0.01214001,0.01002721,0.002146061,0.002668299,0.0004436177,0.0002560255,0.00360989,0.02115412,0.001446382,0.02532488,0.2004057],"study_design_scores_gemma":[0.7639897,0.1568963,0.02741524,0.0003764888,0.002395784,0.001128195,0.0001746958,0.003527439,0.00708173,0.001929773,0.0350102,0.00007439979],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9634313,0.0134245,0.001357961,0.001337753,0.0003280755,0.002862254,0.006161991,0.0001972411,0.01089893],"genre_scores_gemma":[0.9585152,0.005963839,0.003358213,0.002006687,0.0001750514,0.002949668,0.01358891,0.00006384362,0.01337845],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004167152,"threshold_uncertainty_score":0.01394045,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1254734596959532,"score_gpt":0.4444339953628714,"score_spread":0.3189605356669181,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}